Free Trial

Vicarious Surgical (NYSE:RBOT) Announces Quarterly Earnings Results

Vicarious Surgical logo with Medical background
Remove Ads

Vicarious Surgical (NYSE:RBOT - Get Free Report) posted its earnings results on Monday. The company reported ($2.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.69) by $0.26, Zacks reports. The company had revenue of $2.09 million for the quarter. During the same period in the previous year, the company posted ($2.25) EPS.

Vicarious Surgical Stock Up 0.9 %

Shares of NYSE RBOT traded up $0.07 during mid-day trading on Friday, reaching $8.07. 3,430 shares of the company were exchanged, compared to its average volume of 33,000. The company's 50-day simple moving average is $12.30 and its 200-day simple moving average is $10.56. The stock has a market capitalization of $47.68 million, a P/E ratio of -0.78 and a beta of 1.35. Vicarious Surgical has a twelve month low of $4.27 and a twelve month high of $19.00.

Analysts Set New Price Targets

Separately, Piper Sandler cut their target price on shares of Vicarious Surgical from $10.50 to $8.50 and set a "neutral" rating for the company in a research note on Tuesday.

Read Our Latest Stock Analysis on RBOT

Vicarious Surgical Company Profile

(Get Free Report)

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Featured Stories

Earnings History for Vicarious Surgical (NYSE:RBOT)

Should You Invest $1,000 in Vicarious Surgical Right Now?

Before you consider Vicarious Surgical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vicarious Surgical wasn't on the list.

While Vicarious Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

The Future of Healthcare: 3 AI Stocks Leading the Way

The Future of Healthcare: 3 AI Stocks Leading the Way

2025 promises explosive growth for AI, but which companies are making a difference in healthcare? Chris Markoch highlights three stocks leading the charge.

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads